Received Feb 16, 2026
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| IPV | POLIO VIRUS, INACT. (IPOL) | SANOFI PASTEUR | UNK | Y1D49P1 | OT / LL |
patient received a double dose of IPV with no reported adverse event; Initial information received on 06-Feb-2026 regarding an unsolicited valid non-serious case received from a other health professional. This case involves a 4 month old male patient who received a double dose of IPV (VERO) [IPOL] with no reported adverse event. The patient's past medical history, medical treatment(s), vaccination(s) and family history were not provided. On 06-Feb-2026, the patient received a dose of 0.5ml of suspect IPV (VERO) (lot Y1D49P1, expiry date-30-Sep-2027, strength-standard, frequency-once) via intramuscular route in the left thigh for Immunization with no reported adverse event (extra dose administered) (latency-same day). It was reported after she received PENTACEL, and then was also given IPOL. Action taken was not applicable. This suspected adverse reaction report is submitted and classified as a medication error solely and exclusively to ensure the marketing authorization holder's compliance with the requirements set out in the Directive 2001/83/EC and Module VI of the Good Pharmacovigilance Practices. The classification as a medical error is in no way intended, nor should it be interpreted or construed as an allegation or claim made by the marketing authorization holder that any third party has contributed to or is to be held liable for the occurrence of this medication error.